Vlasta Sykorova1, Sarka Dvorakova2, Josef Vcelak2, Eliska Vaclavikova2, Tereza Halkova2, Daniela Kodetova3, Petr Lastuvka4, Jan Betka4, Petr Vlcek5, Martin Reboun6, Rami Katra7, Bela Bendlova2. 1. Department of Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic vsykorova@endo.cz. 2. Department of Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic. 3. Departments of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic. 4. Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic. 5. Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic. 6. Institute of Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague 2, Czech Republic. 7. Department of ENT, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic.
Abstract
BACKGROUND: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are very rare tumors with extremely aggressive behavior. Their comprehensive genetic background is still unclear. Some of the main genetic changes of differentiated thyroid carcinomas, such as mutations in BRAF and RAS genes, as well as changes in CTNNB1, PIK3CA, TP53, AXIN1, PTEN or APC genes leading to the dedifferentiation of the tumors, are described. MATERIALS AND METHODS: DNAs from fresh frozen thyroid tissues of 3 PDTCs and 5 ATCs were extracted. The next-generation sequencing (NGS) approach was used to target 94 genes involved in cancer. The samples were prepared using a TruSight Cancer panel and sequenced with a MiSeq sequencer. Analysis of variants was performed by the MiSeq Reporter and NextGENe software and stringent criteria for prioritization of the variants were used in the Illumina VariantStudio software. RESULTS: Using NGS, we identified 26 genetic changes in 18 genes, novel variants included. CONCLUSION: NGS is a useful tool for searching for new variants and genes involved in PDTC and ATC. It seems that each of these rare tumor types has its own specific genetic background. These data could be helpful for recognizing new genetic markers and targets for future personalized therapy. Copyright
BACKGROUND: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are very rare tumors with extremely aggressive behavior. Their comprehensive genetic background is still unclear. Some of the main genetic changes of differentiated thyroid carcinomas, such as mutations in BRAF and RAS genes, as well as changes in CTNNB1, PIK3CA, TP53, AXIN1, PTEN or APC genes leading to the dedifferentiation of the tumors, are described. MATERIALS AND METHODS: DNAs from fresh frozen thyroid tissues of 3 PDTCs and 5 ATCs were extracted. The next-generation sequencing (NGS) approach was used to target 94 genes involved in cancer. The samples were prepared using a TruSight Cancer panel and sequenced with a MiSeq sequencer. Analysis of variants was performed by the MiSeq Reporter and NextGENe software and stringent criteria for prioritization of the variants were used in the Illumina VariantStudio software. RESULTS: Using NGS, we identified 26 genetic changes in 18 genes, novel variants included. CONCLUSION: NGS is a useful tool for searching for new variants and genes involved in PDTC and ATC. It seems that each of these rare tumor types has its own specific genetic background. These data could be helpful for recognizing new genetic markers and targets for future personalized therapy. Copyright
Authors: Vlad C Sandulache; Michelle D Williams; Stephen Y Lai; Charles Lu; William N William; Naifa L Busaidy; Gilbert J Cote; Rajesh R Singh; Rajyalakshmi Luthra; Maria E Cabanillas Journal: Thyroid Date: 2016-11-29 Impact factor: 6.568
Authors: Soeren Latteyer; Vera Tiedje; Katharina König; Saskia Ting; Lukas C Heukamp; Lydia Meder; Kurt Werner Schmid; Dagmar Führer; Lars Christian Moeller Journal: Endocrine Date: 2016-10-01 Impact factor: 3.633
Authors: Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer Journal: Eur Arch Otorhinolaryngol Date: 2020-02-14 Impact factor: 2.503
Authors: Matthew E Spector; Janice L Farlow; Catherine T Haring; J Chad Brenner; Andrew C Birkeland Journal: Discov Med Date: 2018-05 Impact factor: 2.970
Authors: Matthew W Rosenbaum; Benjamin J Gigliotti; Sara I Pai; Sareh Parangi; Heather Wachtel; Mari Mino-Kenudson; Viswanath Gunda; William C Faquin Journal: Endocr Pathol Date: 2018-03 Impact factor: 3.943